Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE versus NESACAINE MPF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE versus NESACAINE MPF.
BUPIVACAINE HYDROCHLORIDE vs NESACAINE-MPF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine hydrochloride is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the generation and propagation of action potentials and producing reversible local anesthesia.
Nesacaine-MPF (chloroprocaine) is an ester-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking impulse conduction in nerve fibers.
0.25% to 0.5% solution infiltrated locally, up to 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000) per dose; maximum 400 mg per 24 hours. For epidural: 0.5% to 0.75% solution, 15-20 mL for surgical anesthesia.
1% solution: 2.5-30 mL (25-300 mg) subcutaneously or locally; maximum 30 mL per dose. 2% solution: 1.25-15 mL (25-300 mg) subcutaneously or locally; maximum 15 mL per dose.
None Documented
None Documented
Terminal elimination half-life: 2.7 hours (adults); prolonged in neonates (8.1 hours) and patients with hepatic impairment; clinical context: half-life increases with repeated dosing due to accumulation.
Terminal half-life: 3-4 hours (adults); prolonged in hepatic or renal impairment.
Primarily hepatic metabolism (CYP3A4, CYP1A2, and amidases) to pipecoloxylidine and desbutylbupivacaine; less than 5% excreted unchanged in urine; negligible biliary/fecal excretion.
Renal excretion of metabolites; <10% unchanged drug. Biliary/fecal elimination minor.
Category C
Category C
Local Anesthetic
Local Anesthetic